PURA - Puration CBD Beverage Survey Points To Anxiety Treatment Topping Consumer Motivations and Tea as Favorite Beverage
September 18 2019 - 8:29AM
InvestorsHub NewsWire
PURA - Puration CBD Beverage Survey
Points To Anxiety Treatment Topping Consumer Motivations and Tea as
Favorite Beverage
- Analyst Confirms PURA Speculative BUY and $0.25
PPS Target
- PURA Currently Reports Millions in Sales of
EVERx CBD Sports Water
- Survey Conducted as Part of PURA New CBD
Beverage Marketing
- Anxiety Tops Consumers Reported Motivations for
Trying CBD
- Tea Tops Consumers Beverage
Preferences
Dallas, TX -- September 18, 2019 -- InvestorsHub
NewsWire -- Puration, Inc. (USOTC:
PURA) (”PURA”) today announced the results of a CBD infused
beverage market survey conducted by Goldman
Small Cap Research. The survey is part of a pre-marketing
campaign of PURA’s new CBD Infused beer, coffee and tea
beverages. The data collected will be used to target PURA’s
marketing direction for CBD infused beer, coffee and tea. The
survey results show that tea is the consumers first choice beverage
and that the primary reason for consumers to take CBD is to treat
anxiety. The second reason for trying CBD was to treat
inflammation.
“Of those
participants that expressed an interest or desire to try for the
first time or as an occasional user of CBD-infused beverages, our
results showed that 47% preferred
tea.”
“Despite age and
geographic diversity, the majority of users said they use CBD
products to relieve anxiety and/or
inflammation.”
Goldman Small Cap Research Confirms Speculative
Buy and $0.25 PPS Target
PURA is already a leading CBD infused beverage
company having produced over $1 million in CBD Beverages in the
United States last year (2018) and reporting over $1 million in CBD
Beverages for just the first six months of 2019. PURA
has targeted $4 million in sales for 2019.
“PURA Is the Best
Positioned CBD-infused
Provider. With a popular
CBD-infused energy water selling millions worth of beverages this
year, to the expansion into anti-anxiety and anti-inflammatory
characteristics of what looks to be a wildly popular CBD-infused
tea, PURA has the key bases covered. Clearly, the stock doesn’t
reflect the inherent prospects that lie herein. Our target remains
$0.25.”
PURA recently implemented program to introduce
CBD infused versions of existing third-party beverages. The
company has announced plans to introduce a CBD infused beer in
partnership with an existing beer producer and in similar fashion,
PURA has partnered with an existing coffee producer and tea
producer to introduce CBD infused coffee and tea. The company
recently published a presentation on its beer, coffee and tea
initiative that is included in its entirety on the company’s
website. Management
plans to update the company’s beer, coffee and tea strategy in
conjunction with the survey results announced
today.
EVERx CBD Sports Water is available for purchase
on line at www.USMJ.com, hosted by PURA’s partner, North American
Cannabis Holdings, Inc. (USOTC:
USMJ).
To
view the complete Goldman Small Cap Research Survey report,
visit
https://www.goldmanresearch.com/201909181252/Opportunity-Research/survey-results-confirm-pura-new-products-should-be-big-sellers.html
For more information
on Puration, visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Nov 2023 to Nov 2024